Improving the efficiency of clinical trials in multiple sclerosis.

Kathryn C Fitzgerald Maria Pia SormaniSean Apap MangionFrancesca BovisWinson Y CheungGary R CutterPeter FeysMichael D HillMarcus Werner Koch Morgan C McCrearyEllen M MowryJay Jh ParkFredrik Piehl Salter AmberJeremy Chataway

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2023)

Novel trial designs and further development of intermediate outcomes may improve clinical trial efficiency in MS and address novel therapeutic questions.

Keyphrases

clinical trial
multiple sclerosis
phase ii
phase iii
study protocol
open label
double blind
white matter
mass spectrometry
ms ms
adipose tissue
glycemic control